Overture Orthopaedics, a privately held U.S.-based medical device company providing surgeons with innovative joint preservation solutions in sports medicine and orthopaedic surgery, announced it has achieved the $1.0M milestone in sales of its award-winning OvertureTi Knee Resurfacing System.

OvertureTi Knee Resurfacing System implants are designed specifically as an alternative when it is still too early for arthroplasty, but biological repair options are not viable for treating early osteoarthritis and focal cartilage lesions. The system is composed of femoral and tibial implants intended to be used in the partial replacement of the articular surfaces of the knee. These implants were designed with sizing options that allow the surgeon to replace only the diseased or damaged region of the joint while preserving healthy native cartilage and soft tissue. The procedure is referred to as Focalplasty.

"As a cartilage preservation doctor, seeing my younger patients getting older, getting more arthritic while wanting to maintain their active lifestyles, techniques such as meniscus transplantation and osteochondral allograft are less successful; so we need other options such as metallic implants to help us resurface joints and be a key part of our cartilage repair algorithm," said Dr. Bert Mandelbaum, Professor and Vice Chair of the Orthopaedic Surgery Department at Cedars-Sinai, Associate Chief Medical Officer of Major League Soccer, and Team Physician of U.S. Soccer. "I think the Overture solution gives us an ideal alternative solution to deficits of cartilage and bone in the osteoarthritic situation where the knee begins showing signs of a catabolic state. Overture will continue gaining traction as a solution to address this growing subset of patients."

With the ever-increasing active patient population, the number of cartilage restoration surgeries performed annually exceeds 300,000, notably growing each year. A 2021 paper on chondral lesions of the knee in the Journal of Bone and Joint Surgery by Dekker et al., highlights current surgical and biological options for treatment of isolated cartilage defects continue to present significant challenges for patients and surgeons in terms of cost and complexity, including inconsistent healing, donor site morbidity, and degradation over time. According to a study by McCormick et al. that focused on trends in the surgical treatment of articular cartilage lesions in the United States, some procedures such as chondrocyte implantation reach costs as high as $83,073 due to multi-stage surgeries, laboratory processing, associated episode of care, and societal considerations.